Russia has announced that its personalized mRNA cancer vaccine, Enteromix, has shown 100% efficacy and safety in early clinical trials.
Developed by Russia’s National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology, Enteromix uses mRNA technology—similar to that employed in COVID-19 vaccines—to train the immune system to recognize and eliminate cancer cells. What sets this vaccine apart is its personalization for each patient, based on the genetic profile of their individual tumors.
Additionally, Enteromix incorporates four harmless viruses designed to directly target and destroy cancer cells while simultaneously stimulating the body’s immune defenses.
Preclinical trials revealed significant tumor shrinkage of 60-80% and a slowdown in tumor progression. Phase 1 clinical trials involved 48 volunteers, and the results indicated 100% efficacy in activating immune responses, with no severe side effects reported.
Currently, Enteromix is focusing on treating colorectal cancer, with versions targeting glioblastoma and melanoma also in development.
The next step is to obtain regulatory clearance from Russia’s ministry of health. If approved, Enteromix could become the first personalized mRNA cancer vaccine available to the public.
